Nat Genet: Application of CCS1477 Drug Slows Prostate Cancer Development
Researchers at Emory University have elucidated for the first time the detailed mechanism by which prostate cancer cells transform into an exceptionally aggressive form known as neuroendocrine prostate cancer (NEPC). This highly resistant variant, which affects approximately 20% of patients with advanced prostate cancer, is unresponsive to conventional hormone therapy. Their study, published in Nature Genetics, offers crucial insights into why some tumors develop treatment resistance.
The research team pioneered the creation of the world`s first 3D map illustrating DNA remodeling within prostate cancer cells. Their findings revealed that the proteins FOXA2 and NKX2-1 effectively reprogram genetic instructions, activating genes typically associated with brain and lung cells, thereby increasing the tumor`s aggressiveness. These genetic alterations, in turn, trigger the enzymes CBP and p300, leading to the activation of new oncogenes and accelerating disease progression.
The team further investigated the feasibility of blocking this transformative process. In both laboratory and animal models, the application of CBP/p300 inhibitors, including the drug CCS1477 (currently undergoing clinical trials), significantly decelerated tumor growth. This breakthrough paves the way for the development of targeted therapies specifically against NEPC.
According to the researchers, this discovery could form the foundation for developing novel treatment regimens designed to prevent tumors from evolving into this lethal form. For patients battling advanced prostate cancer, this represents a promising outlook for extended survival and the availability of effective, personalized therapies.
